Clinical Trial Update: Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia [Phase 3]

View source ↗

Summary

Long-term safety data from a safety-extension study of interferon gamma-1b (ACTIMMUNE) in children and young adults with Friedreich's Ataxia were reported after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• ACTIMMUNE (interferon gamma-1b)

Snippet

Sponsor: Amgen | Conditions: Friedreich's Ataxia | Phase 3 | Status: COMPLETED | Results posted: 2018-05-01